Scienture Holdings, Inc. (Nasdaq: SCNX) has entered into a securities purchase agreement with institutional investors to purchase 3,225,000 shares of common stock at an offering price of $1.20 per share.
The gross proceeds for the offering are expected to be approximately $3.9 million before deducting fees and expenses.
The offering is set to close on August 15, 2025, subject to customary conditions.
Securities Purchase Agreement
Securing funds through a stock offering at $1.20 per share.
Gross Proceeds
Expected to reach $3.9 million before expenses.
Closing Date
Scheduled for August 15, 2025.
- The securities purchase agreement will provide funding for Scienture's pharmaceutical operations.
- Maxim Group LLC is acting as the sole placement agent for the offering.
Scienture Holdings, Inc.'s successful entry into the securities purchase agreement marks a milestone in securing funding for its pharmaceutical endeavors.